Beikabuzukan
日本語
Watchlist

Obsidian Therapeutics Inc.

Overview

Financials

Units: $M (per-share in $, ratios in %)

Revenue & profit

Margins

Valuation

Multiples at each fiscal year end (annual) and current (TTM)

Valuation history

Segments

Revenue breakdown (annual, $B). Segments depend on each year’s disclosure.

By product

By region

Dividends & earnings

Annual dividend per share ($, split-adjusted)

EPS (diluted), last 16 quarters ($)

Company info

A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.